Browse by Medical Category
Allergy & Clinical Immunology Unit
Accepting New Patients
Allergy & Immunology
Go To Programs
Go To Programs
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
I received my medical degree from University College Cork of the National University of Ireland in 1980. After residency training in internal medicine in Cork and Dublin, I undertook Fellowship training and Allergy and Immunology at McMaster University in Canada, as well as serving as Chief Medical Resident. I followed this with a 3 year laboratory-based research Fellowship in the Department of Hematology Oncology at Tufts University-New England Medical Center. From 1991-2001, I was a staff physician in the Division of Allergy at that institution and Assistant Professor of Medicine at Tufts University. I co-directed the clinical practice and worked part-time in a private practice between 1996 and 2001.
In 2001, I was appointed Clinical Director of the allergy unit at Massachusetts General Hospital. In 2004, I assumed an additional role as Director of the Fellowship Program in Allergy and Immunology in the Division of Rheumatology, Allergy and Immunology. I am an Associate Professor of Medicine at Harvard Medical School.
In 2007, I embarked on a novel study of dendritic cell function in patients with asthma. Previously, my research was clinically based and related predominantly to health care utilization and adherence patterns in asthma patients. During fellowship, I studied lymphocytotoxic and antiphospholipid antibodies in SLE and use of variable region genes usage in autoantibodies and IgE. I also evaluated in situ PCR. During residency, I co-authored publications in the field of rheumatology and gastroenterology.
View my most recent publications at PubMed
A team of Massachusetts General Hospital investigators has found no evidence that allergen immunotherapy carries a risk of infection. Although the sterility of these “allergy shots” has not been a concern, the organization that sets standards for the quality and safety of medications has proposed new guidelines that place them in the same category as preparations intended for intravenous or spinal administration.
Back to Top